☰

Adimab

Unifying data across 600 antibody programs

Industry
Antibody Discovery and Engineering (CRO)
Headquarters
Lebanon, New Hampshire, United States
Public information as of
February 2026

A4BEE prepared this analysis from publicly available sources. It reflects our own reading of Adimab's published strategy and is not endorsed by, or produced in cooperation with, Adimab. Company website

Strategic priorities

Adimab runs a yeast-based antibody discovery and engineering platform for 140+ biopharma partners, with a portfolio of 600+ royalty-bearing programs and 74+ programs in the clinic as of early 2024. The company reports zero programs discontinued due to developability issues, a record it ties to its 12-assay biophysical characterization suite and partner-first model. The platform typically delivers purified, full-length human IgGs within four months from antigen to characterization.

The strategic context in 2024-2025 is operational scale: a 50,000+ square foot expansion at the Lebanon, New Hampshire campus, headcount growth of around 40% over three years, and the 2024 launch of the Adimab Royalty Company (ARC) to manage late-stage and approved assets separately from the core discovery engine. 51 technical milestones were reached in 2024 across 62 new programs, and 17 new partnership agreements were signed in the same year.

The portfolio is moving toward harder biology: G Protein-Coupled Receptors (GPCRs), ion channels, T-cell receptors (TCRs), and multispecific antibody formats. These targets require native membrane environments during selection, larger variant spaces, and tighter integration between wet-lab screening and computational models. The same data plumbing that supports them has to keep up with 600-800 unique sequence combinations characterised in a single primary discovery campaign.

Challenges we see

  • R&D Discovery

    Selecting antibodies against membrane-obligate proteins without antigen mimetics

    Adimab has identified membrane-obligate proteins (GPCRs, ion channels) as a major technical frontier. These targets require discovery workflows that maintain the protein in its native cellular environment rather than working with soluble mimics.

    Where the selection environment has to preserve a native membrane, the supporting lab infrastructure — perfusion, sensors, control of library sorting — has to be tuned to that condition, so the workflow for a difficult target differs from the standard IgG path from the start.

  • Data Integration

    Reconciling data across the high-throughput expression, analytics and molecular biology groups

    A single primary discovery campaign generates 600-800 unique H3/L3 sequence combinations, each characterized across 12 developability assays spanning sequence analysis, biophysical characterization and kinetic data. The data are produced across multiple core groups, including molecular biology, analytics, high-throughput expression and computational biology.

    Where sequence, expression and biophysical results live in separate systems, the make-test cycle relies on manual reconciliation, so the time between running an experiment and ranking candidates is set by data plumbing rather than by the science.

  • Digital Modeling

    Validating predictive models against human pharmacokinetic outcomes

    Adimab increasingly uses AI-guided engineering and in silico descriptors to predict biophysical behavior and clinical potential. The current Red Flag scoring system benchmarks candidates against the worst-performing 10% of approved antibodies, drawing on multi-source human clearance data.

    Where upstream biophysical metrics and downstream human pharmacokinetic (PK) data are described in different terms, the predictive models trained on one are hard to validate against the other, so the move from empirical scoring to predictive nomination needs a shared data substrate.

  • Operations Infrastructure

    Scaling digital coordination across the expanded Lebanon campus

    The 50,000+ square foot expansion at the Lebanon campus, 40% headcount growth and program volume scaling from 400 to 600+ royalty-bearing programs all add to the operating pressure. The integration of legacy lab systems with new facilities creates a risk of fragmented equipment behaviour across the campus.

    Where teams operate with high local efficiency but low synchronization across the campus, the know-how of senior scientists stays in their heads rather than flowing through shared systems, so the technical standard becomes harder to keep consistent as the organization grows.

  • Pipeline Discovery

    Characterising multispecific antibody variants at platform speed

    The move toward bispecific and multispecific antibodies requires specificity, affinity and valency to be optimized simultaneously, with parametric variants such as linkers and V-domain orientation expanded into the test program.

    Where variant space for a single program grows by an order of magnitude, the time to characterise each candidate sets the ceiling on program throughput, so the platform's data and automation layer has to absorb the bigger parametric sweep without slowing the lead nomination step.

Opportunities, by urgency and business impact

Each bubble is one opportunity, numbered to match the list below. Further right means it bites sooner; higher means a bigger effect on the business. A bigger bubble means a bigger implementation effort.

Source: A4BEE analysis of public sources

  1. Unifying make-test-cycle data across the 12-assay developability suite

    Data from sequence, expression, biophysical characterization and kinetics are produced in separate systems and reconciled manually or semi-manually, so a 600-800 combination campaign involves significant time spent on data handling rather than scientific analysis.

    An ontology-based data platform that loads every assay output against a shared model lets Red Flag scoring run on the same data the scientist sees, and lets candidate ranking be triggered as soon as the last assay completes instead of waiting for the data team to reconcile.

    • Adimab research materials, 2024-2025
    • PepTalk 2024, high-throughput expression data management

  2. Connecting the expanded Lebanon campus as a single Lab of the Future

    The 50,000+ square foot expansion adds equipment types and scales that risk heterogeneous, siloed lab environments where data cannot flow between bioreactors, chromatography systems and analytical instruments.

    A campus-wide digital lab framework based on Module Type Package (MTP) and OPC UA (Open Platform Communications Unified Architecture) standards lets the new wing arrive with interoperability built in, so equipment can be reconfigured between IgG, VHH, TCR and multispecific projects without manual data plumbing.

    • Adimab expansion public statements, 2024
    • Adimab platform partner materials

  3. Building predictive developability models over human PK data

    Wet-lab biophysical characterization is expensive, so suboptimal candidates may only be identified late in the funnel. In silico tools face validation discrepancies against human clearance data sourced from multiple studies.

    A digital twin of the yeast-based discovery process that ingests both upstream biophysical metrics and historical human PK outcomes lets Red Flag scoring evolve from empirical benchmarking to a predictive model, so partners see a candidate profile that is anchored to clinical history rather than to a static rule.

    • Adimab research materials on developability workflows
    • Industry assessments on in silico PK prediction

  4. Accelerating affinity maturation for difficult membrane targets

    GPCRs and ion channels require native membrane environments during selection, which makes them slower and more resource-intensive than standard IgG discovery, limiting capacity as partner demand for these targets grows.

    An integrated microfluidics-and-machine-learning loop where the model proposes informative variants, the microfluidic platform screens them under native conditions, and the results feed back into the model shortens the affinity maturation cycle for difficult targets to a pattern the platform can repeat.

    • Adimab pipeline update, complex target workflows
    • PepTalk 2024, machine learning in antibody discovery

  5. Standing up ESG reporting at the scale partners now require

    Adimab's public ESG reporting maturity trails that of larger peers, and partners and investors are increasingly asking for supply chain accountability and structured carbon intensity tracking from their discovery suppliers.

    Digitalising water, energy and waste use across the expanded Lebanon campus and reporting it through a single ESG backbone lets Adimab meet the partner procurement language that is becoming standard, without spinning up a parallel reporting operation.

    • Industry ESG reporting trends for biotech discovery suppliers
    • Adimab expansion context, 2024

What we'd propose

  • Enterprise AI

    Ontology-based data platform for the 12-assay developability suite

    We build an ontology-based data platform that ingests sequence, expression and biophysical data from every assay in the 12-assay suite, so Red Flag scoring and candidate ranking run on the same dataset the scientist sees, and the 600-800 combination make-test cycle is reconciled by the platform rather than by hand.

    • Unified data ingestion

      One path for every assay stream

      Connect the molecular biology, analytics, high-throughput expression and computational biology systems through standardized ontologies and ETL (extract, transform, load) pipelines so 600-800 unique H3/L3 sequence combinations are mapped to their kinetic and biophysical results without manual reconciliation.

    • Developability Red Flag scoring as a service

      Real-time candidate ranking

      Encode the existing Red Flag scoring rules as a digital service that runs on the unified dataset, so candidates are ranked against the historical biophysical limits of approved antibodies as soon as the last assay completes.

    • Cross-group data harmonization

      Shared view across core groups

      Give the Molecular Core, Analytics and High-Throughput Expression groups a single logical view of the same data, so the correlation between early developability metrics and later PK outcomes is visible at the workbench rather than reconstructed in a separate analysis.

    • Manual data transfer time across the make-test cycle drops as the platform takes over reconciliation.
    • Red Flag scoring runs on the unified dataset, so candidate ranking is consistent across programs.
    • Cross-group data harmonization lets the next research question be asked once, against one dataset.

    We've done this before

    See how we do Enterprise AI
  • Digital Lab

    MTP-based digital lab for the expanded Lebanon campus

    We design and connect the new 50,000+ square foot wing as a digital lab using Module Type Package (MTP) and OPC UA standards, so bioreactors, chromatography systems and analytical instruments arrive interoperable and the campus can switch between IgG, VHH, TCR and multispecific programs without re-plumbing.

    • Campus-wide MTP integration

      Universal equipment communication

      Connect the new facility using MTP and OPC UA standards so that bioreactors, chromatography systems and scales communicate in a unified format, regardless of vendor.

    • Process automation engine

      Reduced manual bioprocess steps

      Automate the routine steps of bioprocess management so that scientists spend more time on engineering decisions and less on monitoring, without losing the human-in-the-loop checkpoints that the platform depends on.

    • Remote operational visibility

      HMI/SCADA-level oversight

      Provide real-time oversight of discovery campaigns through secure dashboards, so partners can see program progress against their milestones without raising visibility tickets.

    • Lab equipment can be reconfigured rapidly between IgG, VHH, TCR and multispecific projects.
    • Centralized IT management keeps software versions consistent across the expanded facility.
    • Operational visibility extends to partner dashboards, so the program milestone conversation is data-led.

    We've done this before

    See how we do Digital Lab
  • Digital Lab

    Microfluidic-ML loop for membrane-obligate targets

    We integrate microfluidic screening with an iterative machine learning layer tailored to GPCR and ion channel workflows, so binding predictions propose the most informative variants, the microfluidic platform tests them under native conditions, and the resulting data sharpens the model for the next round.

    • Iterative ML refinement

      Each round sharper than the last

      Feed microfluidic validation results back into the machine learning model so that affinity maturation for poorly behaved GPCRs and ion channels improves with every cycle, while preserving the native membrane environment the target requires.

    • In silico binding simulation

      Fewer wet-lab cycles

      Use digital twins to model acidic amino acid scanning and pH dependency of candidates before commissioning a wet-lab run, so the platform enters each microfluidic cycle with a smaller, better-targeted candidate set.

    • Custom hardware-software prototypes

      Specialised control systems

      Develop the specialised control systems required for membrane-obligate protein discovery workflows, including custom perfusion and sensing setups for native membrane environments.

    • Membrane target workflows become as standardised as the current IgG platform.
    • The platform's scope extends to TCR and multispecific antibodies without losing the 0% discontinuation record.
    • Process know-how from senior scientists is captured into the model rather than living only in their heads.

    We've done this before

    See how we do Digital Lab
  • Digital Lab

    Retrofitting lab equipment for data interoperability

    We retrofit existing lab equipment across the Lebanon campus so that every instrument publishes data through OPC UA or MQTT (lightweight messaging protocols for industrial data) into the unified platform, breaking vendor lock-in and turning legacy equipment into a contributor to the data substrate.

    • Legacy system revitalization

      Old equipment, new data path

      Connect existing lab equipment to the unified data platform through standardized industrial protocols, so data islands that previously had to be manually exported become live inputs to the platform.

    • Manufacturability feedback loop

      Upstream and downstream connected

      Link early-stage yeast-display data with downstream process parameters, so that candidates with suboptimal manufacturability are flagged before significant resources are committed.

    • MTP-compliant prototype skids

      Modular bioreactor skids

      Accelerate the release of new upstream bioreactors and media preparation skids through MTP-compliant software and custom interface design, so gram-quantity production is faster to commission.

    • Equipment from any vendor can contribute to the platform's data substrate.
    • Developability feedback is generated continuously rather than reviewed at quarterly checkpoints.
    • New skids arrive with the same data contract as the rest of the campus.

    We've done this before

    See how we do Digital Lab
  • Digital Lab

    High-fidelity digital twin of the yeast discovery process

    We build a high-fidelity digital twin of the yeast-based discovery and engineering workflow, so the platform's process know-how is captured in a simulation environment and predictive lead selection can be exercised against historical PK data before candidates are nominated.

    • Yeast platform digital twin

      Discovery workflow in simulation

      Replicate the yeast-based discovery and engineering platform digitally, so library sorting, expression and characterization workflows can be simulated before wet-lab execution.

    • PK correlation engine

      Upstream metrics anchored to outcomes

      Train predictive models against historical human clearance data alongside upstream biophysical metrics, so the predictive engine learns from both sources in the same model.

    • Process know-how capture

      Expertise that scales

      Capture the tacit knowledge of experienced scientists into the computational models, so institutional expertise scales with the 40% headcount growth and 600+ program volume.

    • Lead selection becomes predictive rather than purely empirical.
    • Tacit expertise becomes a model asset rather than a per-scientist dependency.
    • The same digital twin can be extended to GPCR and multispecific workflows as the platform grows.

    We've done this before

    See how we do Digital Lab

Digital maturity: today and target

Scored out of 100 across six dimensions. The target is what Adimab's own published ambition implies — not a perfect score.

Source: A4BEE analysis of public sources
Data interoperability 42 → 88
Sequences and assay results live in systems that exchange data through manual or semi-automated processes; the move to an ontology-based industrial data platform unifies the molecular biology, analytics, high-throughput expression and computational biology groups against one model.
Lab automation (MTP) 48 → 85
Discovery is high-throughput but 30+ device types are not yet integrated into a Plug & Produce (modular, reconfigurable equipment) environment; the Lebanon campus expansion is the catalyst for the shift.
Predictive modeling 55 → 92
Current Red Flag scoring is empirical; the target state requires a digital twin trained on both upstream biophysical metrics and historical human PK data, with validation against clinical outcomes.
OT/IT convergence 40 → 80
Rapid headcount growth and facility expansion put pressure on operational technology consistency; the target state requires centralized supervisory control and paperless lab processing across the expanded campus.
Complex target support 52 → 90
GPCR and TCR workflows are proprietary but more resource-intensive than standard IgG; the target state requires automated microfluidic-ML loops for membrane-obligate proteins.
ESG transparency 15 → 70
Public ESG reporting trails that of larger peers; the target state requires digitalised resource tracking and structured carbon intensity reporting to meet partner demands.

Check this yourself

Our Service Portal has free self-assessments and market comparisons. These are the ones that line up with what we've read above — no sales call required.

Think we've read this right?

Talk to us

Related reading

This is an independent analysis prepared by A4BEE from publicly available information as of February 2026. It reflects A4BEE's own interpretation and opinion, is not affiliated with, endorsed by, or verified with Adimab, and may be incomplete or inaccurate. All company names and trademarks are the property of their respective owners. To request a correction or removal, contact [email protected].